J30
Conditions
Interventions
Group 1: Patients of the ENT University Clinic Freiburg for whom biologic therapy was started by 31.10.2022 due to CRSwNP according to the existing indication criteria.
-the patient undergo endonasal
Sponsors
HNO Uniklinik
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Age = 18 years at therapy initiation - Diagnosis of severe therapy-resistant chronic rhinosinusitis with nasal polyposis and indication for therapy with one of the approved biologics at the ENT University Hospital Freiburg in the analysis period 2019 to 2022. - Consent to data collection
Exclusion criteria
Exclusion criteria: Age < 18 years at initiation of therapy - Lack of indication for biologic therapy - Lack of consent to data collection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Change in SNOT-22 quality of life as difference from baseline before biologic therapy 1 year after therapy initiation. - Change in nasal polyp score as difference from baseline before biologic therapy 1 year after initiation of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in SNOT-22 quality of life as difference from baseline before biologic therapy 4 weeks, 3 months and 6 months after therapy initiation. - Change in nasal polyp score as a difference from baseline before biologic therapy 4 weeks, 3 months and 6 months after initiation of therapy - Change in ability to smell - Adverse events during therapy - Number of sinus surgeries during ongoing biologic therapy - Change of biologic due to non-response or complications - Number of previous surgeries - Demographic data (age, gender) - Comorbidities (bronchial asthma, ASA intolerance) | — |
Countries
Germany
Contacts
Public ContactTanja Hildenbrand
Uniklinik Freiburg
Outcome results
None listed